

Supplementary Figure 1: Timeline for adoptive CD8 transfer and isolation of splenic DC from CD8 recipients for further analysis



Supplementary Figure 1: Timeline for adoptive CD8 transfer and isolation of splenic DC from CD8 recipients for further analysis

Five million PLP-CD8 or OVA-CD8 were adoptively transferred into wild-type recipient mice on day -1. Mice were immunized with PLP₁₇₈₋₁₉₁ (100 μg) on day 0 and were given two doses of pertussis toxin (PTX, 250 ng) on days 0 and 2 to induce EAE. Splenic DC were isolated from PLP-CD8 recipients (PLP-CD8-DC) or OVA-CD8 recipients (OVA-CD8-DC) on designated time-points post-EAE induction for further analysis. DC were isolated on days 1, 3, 6 and 13 for phenotypic characterization by flow cytometry, on days 3 and 13 for the assessment of their cytokine profile and on day 12 for evaluating their capacity to support CD4⁺ T cell proliferation.


Supplementary Figure 2: PLP-CD8-DC demonstrate reduced capacity to support CD4⁺ T cell proliferation



Supplementary Figure 2: PLP-CD8-DC demonstrate reduced capacity to support CD4⁺ T cell proliferation

Five million PLP-CD8 or OVA-CD8 were adoptively transferred into wild-type recipient mice on day -1. Mice were immunized with PLP₁₇₈₋₁₉₁ (100 μ g) on day 0 and were given two doses of pertussis toxin (PTX, 250 ng) on days 0 and 2 to induce EAE. Splenic DC were isolated from PLP-CD8 recipients (PLP-CD8-DC) or OVA-CD8 recipients (OVA-CD8-DC) on day 12 post-EAE induction and cultured with CFSE-labelled responder CD4⁺ T cells from PLP-immunized mice at a 1:10 ratio (DC: CD4⁺) with increasing concentrations of PLP₁₇₈₋₁₉₁ (0 to 50 μ M) for 5 days. Cells were stained with Live-Dead Blue and surface marker and analyzed using flow cytometry. CD4⁺ T cell proliferation was quantified as the CFSE dilute fraction of live CD4⁺ T cells. Representative pseudocolor plots are shown in the figure.


Supplementary Figure 3: Gating strategy for the phenotypic characterization of conventional DC subsets using flow cytometry



Supplementary Figure 3: Gating strategy for the phenotypic characterization of conventional DC subsets using flow cytometry

PLP-CD8-DC and OVA-CD8-DC were isolated on days 1, 3, 6 and 13 post-EAE induction and stained with Live-Dead Blue and surface markers for the phenotypic characterization of conventional DC (cDC) subsets using flow cytometry. After gating on Live CD45+ singlets; T cells, B cells and pDC were excluded and cDC were identified as CD11chi MHC-IIhi. cDC subsets were further distinguished as cDC1 (CD8a+CD11b-) and CD11b+ cDC (CD8a-CD11b+).


Supplementary Figure 4: PLP-CD8-DC subsets express higher levels of costimulatory and regulatory markers on day 13 post-EAE induction



Supplementary Figure 4: PLP-CD8-DC subsets express higher levels of costimulatory and regulatory markers on day 13 post-EAE induction

Expression of the costimulatory and regulatory markers on live cDC1 and CD11b+cDC isolated on day 13 post-EAE induction was measured in geometric mean fluorescence intensity (gMFI). The cDC1 and CD11b+cDC subsets of PLP-CD8-DC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and cD11b+cDC displayed higher expression of CD83 and of CD40, CD83, CD86, LAP and PD-L2, than OVA-CD8-DC, respectively (N = 3, T-test, N = 1) and N = 10 and N


Supplementary Figure 5: PLP-CD8-DC subsets exhibit higher coexpression of costimulatory and regulatory markers on day 13 post-EAE induction



Supplementary Figure 5: PLP-CD8-DC subsets exhibit higher co-expression of costimulatory and regulatory markers on day 13 post-EAE induction

The representative pseudocolor plots demonstrate the co-expression of CD86 with CD83 and PD-L2 on live cDC1 and CD11b+cDC isolated on day 13 post-EAE induction.


Supplementary Figure 6: PLP-CD8 enhance maturation and regulatory marker expression on cDC subsets in vitro



Supplementary Figure 6: PLP-CD8 enhance maturation and regulatory marker expression on cDC subsets in vitro

DC from PLP-immunized mice were cultured with PLP-CD8 or OVA-CD8 in increasing ratios (1:1.25 to 1:5, DC: CD8⁺) in the presence of PLP₁₇₈₋₁₉₁ (20 μ g/ml) and rIL-2 (10 pg/ml) for 24 hours. Freshly isolated DC (*Direct ex vivo*) and DC incubated without CD8⁺ T cells (No CD8⁺) were used as controls. Following incubation, the expression of costimulatory and regulatory markers on live cDC1 and CD11b⁺ cDC subsets was measured in geometric mean fluorescence intensity (gMFI) using flow cytometry. Panels **A** and **B** show the expression of the indicated markers on live cDC1 and CD11b⁺ cDC, respectively, at a DC: CD8 ratio of 1:5. **C-D**) Expression of costimulatory and regulatory markers was significantly higher on live **C**) cDC1 and **D**) CD11b⁺ cDC following incubation with PLP-CD8 (N = 3, Owo-Way ANOVA with multiple comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).


Supplementary Figure 7: Trans-well Assay: Experimental Setup



Supplementary Figure 7: Trans-well Assay: Experimental Setup

The interaction of PLP-CD8 with either cDC subset and its effect on the other subset were studied using a trans-well assay. cDC1 and CD11b⁺ cDC, were FACS-sorted from PLP-immunized mice 10 days post-immunization. CD11b⁺ cDC (80,000) were seeded into the wells and cDC1 (20,000) into the inserts of the tissue-culture plate. PLP-CD8 (500,000) were added to either subset creating five conditions: Condition **A**: cDC1 in the inserts and CD11b⁺ cDC in the wells without PLP-CD8; Condition **B**: cDC1 and PLP-CD8 in the insert and CD11b⁺ cDC in the wells; Condition **D**: PLP-CD8 in the inserts and CD11b⁺ cDC in the wells without cDC1; and Condition **E**: PLP-CD8 in the inserts and cDC1 in the wells without CD11b⁺ cDC. The cells were incubated with PLP₁₇₈₋₁₉₁ (20 μg/ml) and rIL-2 (10 pg/ml) for 24 hours, following which, supernatants were collected, and cells were analyzed using flow cytometry. These illustrations were generated in BioRender.


Supplementary Figure 8: Paracrine effects of PLP-CD8 on CD11b+cDC likely augmented by cDC1



Supplementary Figure 8: Paracrine effects of PLP-CD8 on CD11b+cDC likely augmented by cDC1

Following 24 hours of incubation in the trans-well assay, the expression of costimulatory and regulatory markers on live CD11b⁺ cDC was measured in geometric mean fluorescence intensity (gMFI). **A)** Shows the expression of these markers in different conditions. **B)** MHC-II expression on CD11b⁺ cDC was significantly reduced in Condition C (CD11b⁺ cDC in direct contact with PLP-CD8). CD11b⁺ cDC in Condition B (cDC1 in direct contact with PLP-CD8) displayed significantly higher expression of CD86 than in Condition A (cDC1 separated from CD11b⁺ cDC without PLP-CD8) and in Condition C. Expression of PD-L1 and PD-L2 on CD11b⁺ cDC was significantly higher in Condition B than in Condition C (N = 3, One-Way ANOVA with multiple comparisons, ns = not significant, *p < 0.05, ****p < 0.0001).


Supplementary Figure 9: Coexpression of costimulatory and regulatory molecules on live CD11b⁺ cDC in different trans-well conditions



Supplementary Figure 9: Coexpression of costimulatory and regulatory molecules on live CD11b⁺ cDC in different trans-well conditions

This panel shows the co-expression of CD86 or MHC-II with other costimulatory and regulatory markers on live CD11b+cDC in Conditions A-D in pseudocolor plots.


Supplemental Figure 10: PLP-CD8-conditioned supernatants promote survival, maturation, and regulatory marker expression in CD11b⁺ cDC



Supplemental Figure 10: PLP-CD8-conditioned supernatants promote survival, maturation, and regulatory marker expression in CD11b+cDC

CD11b⁺ cDC (45,000) were incubated with 500 μ l of complete media or supernatants from the four conditions of the trans-well assay, sups A-D, for 24 hours and analyzed using flow cytometry. Costimulatory and regulatory markers on live CD11b⁺ cDC were quantified in geometric mean fluorescence intensity (gMFI). Incubation with Media had varying effects on the expression of different markers on CD11b⁺ cDC. MHC-II expression on CD11b⁺ cDC was highest when incubated with Media and was significantly higher with sup B (cDC1 in direct contact with PLP-CD8) than with other sups. In contrast, the expression of CD80, CD86, PD-L1 and PD-L2 on CD11b⁺ cDC was lower with sup A (cDC1 separated from CD11b⁺ cDC without PLP-CD8) than with other sups from conditions involving PLP-CD8 (N = 3, One-Way ANOVA with multiple comparisons, *p < 0.05, **p < 0.01, ****p < 0.001, *****p < 0.0001).


Supplementary Figure 11: Single-cell RNA-sequencing – Unsupervised clustering and cell type annotation



Supplementary Figure 11: Single-cell RNA-sequencing – Unsupervised clustering and cell type annotation

PLP-CD8-DC and OVA-CD8-DC isolated on day 12 post-EAE induction were prepared for single-cell RNA sequencing (Parse Biosciences). Data were analyzed using the Seurat package in R. Unsupervised clustering identified 9 distinct Seurat clusters. Canonical gene expression was used to designate different cell types. Panel A) shows the dot plot of canonical gene expression in annotated Seurat clusters. Clusters 0, 1, 2, 3, and 6 exhibited similar gene expression patterns consistent with cDC2 or related DC subsets, characterized by the expression of CD11b (*Itgam*) and SIRP-α (*Sirpa*). Clusters 3 and 6 were designated as Migratory cDC due to their expression of *Ccr7*. The remaining four clusters in this group lacked CD24 (*Cd24a*), CD64 (*Fcgr1*), and CD88 (*C5ar1*) but expressed CD26 (*Dpp4*), making monocyte-derived DC (moDC) or inflammatory DC unlikely and supporting their classification as cDC2. For clarity and convenience, we collectively refer to this group as CD11b⁺ cDC.

Supplementary Figure 12: Single-cell RNA-sequencing – Differential gene expression (DGE) and downstream analysis



Supplementary Figure 12: Single-cell RNA-sequencing – Differential gene expression (DGE) and downstream analysis

Differential gene expression (DGE) was analyzed within each annotated cluster between the two CD8 treatments, PLP-CD8 and OVA-CD8. No significant DGE was observed in B cells, Macrophages, pDC-like cells and Migratory cDC. The highest number of differentially expressed genes were found in CD11b⁺ cDC followed by cDC1. Panel **A**) shows a heatmap of representative genes upregulated in the CD11b⁺ cDC subset from PLP-CD8 recipients. Nichnet analysis was performed to model potential intercellular communication between CD11b⁺ cDC and other DC subsets and non-DC cell types. A list of prioritized ligands important for intercellular communication was generated from the dataset with their target and receptor genes upregulated in CD11b⁺ cDC from PLP-CD8 recipients. Panel **B**) shows the ligand-receptor and ligand-target networks using Circos plots. Panel **C**) shows significant upregulation of *Foxo3*, a key immunoregulatory transcription factor in cDC1 and CD11b⁺ cDC from PLP-CD8 recipients identified using DecoupleR analysis.